Towards this end, when PLX4720 was co-administered with TRAIL, in TRAIL sensitive DLD-1 cells, TRAIL induced apoptosis was abrogated indicating wild-type BRAF and not mutant KRAS, also present in DLD-1, as the exclusionary factor for colon cancer treatment with PLX4720. Here, KRAS is linked to colonic neoplasm.